Featured Research

from universities, journals, and other organizations

Fortified Drink For Pregnant, Lactating Women

Date:
April 26, 1999
Source:
Cornell University
Summary:
A fortified orange-flavored powdered drink has proved so successful in improving the health of Tanzanian children that the Cornell University and Tanzanian teams who tested it now want to see if it will do the same for pregnant and lactating women in developing countries.

ITHACA, N.Y. -- A fortified orange-flavored powdered drink has proved so successful in improving the health of Tanzanian children that the Cornell University and Tanzanian teams who tested it now want to see if it will do the same for pregnant and lactating women in developing countries.

The Micronutrient Initiative of Canada has provided a $165,000 grant to Michael C. Latham to conduct a two-year study of 350 pregnant women. He will seek to determine the effectiveness of a simple drink in improving the iron and general nutritional status of pregnant and lactating women in Tanzania. The drink is made by mixing about two tablespoons of powder, fortified with 11 vitamins and minerals, in a glass of water.

Latham is professor of international nutrition at Cornell and a physician who was director of Cornell,s Program in International Nutrition for 25 years. His collaborators on the study include Cornell colleagues Deborah Ash and Diklar Makola, M.D., and Tanzanian collaborators, Godwin Ndossi, Cornell Ph.D. '92, and Simon Tatala, M.D.

Rather than using megadoses of nutrients, vitamin pills or fortified foods to boost the diets of Tanzanian children, who are commonly deficient in many nutritional areas, the researchers found that this new approach was very effective and had other advantages. Latham found that the fortified drink not only significantly improved nutritional deficiencies but also brought almost twice as much weight gain and 25 percent greater gain in height in children who consumed the drink versus children who drank a placebo. Among the consumers of the fortified drink, most of the children with moderately severe anemia showed significant improvement in iron levels while many of the consumers of the nonfortified drink showed a worsening.

Latham notes that between one- and two-thirds of pregnant women in the developing world suffer from anemia, and many do not take iron pills regularly. Many pregnant women are at risk of iodine deficiency, which can compromise mental development in their babies. Because many infants in developing countries are at risk for vitamin A deficiency, Latham hopes that the drink will reduce this problem by boosting the vitamin A content of breast milk.

The drink supplies 30 percent to 120 percent of the U.S. recommended dietary allowances for 11 nutrients. Specifically, the fortified orange-flavored powder contains iron, zinc, iodine, vitamins A, C and E, folic acid, niacin, thiamin, riboflavin and pyrodoxine.

"Whereas other researchers stress megadoses to relieve particular deficiencies, this approach can address several deficiencies using physiological doses," noted Latham. "It is simple, could be easily manufactured locally and widely distributed. In a feasibility study, we also found that the pregnant women said they liked the drink and would take it regularly."

The studies on children taking the drink currently are being replicated in the Philippines, and Latham is consulting with UNICEF and others about getting the powder manufactured locally in Tanzania and the Philippines. The experimental batch of the powder was manufactured by the Procter and Gamble Co.

Related World Wide Web sites: The following sites provide additional information on this news release. Some might not be part of the Cornell University community, and Cornell has no control over their content or availability.

-- For more information on the 1998 study on the drink and children in Tanzania: http://www.news.cornell.edu/releases/April98/drink.health.ssl.html

-- For more information on the Division of Nutritional Sciences at Cornell:

http://www.human.cornell.edu/dns/dnshome.html

-- For more information about Michael Latham:

http://www.human.cornell.edu/dns/dnsfac/latham.html


Story Source:

The above story is based on materials provided by Cornell University. Note: Materials may be edited for content and length.


Cite This Page:

Cornell University. "Fortified Drink For Pregnant, Lactating Women." ScienceDaily. ScienceDaily, 26 April 1999. <www.sciencedaily.com/releases/1999/04/990426062750.htm>.
Cornell University. (1999, April 26). Fortified Drink For Pregnant, Lactating Women. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1999/04/990426062750.htm
Cornell University. "Fortified Drink For Pregnant, Lactating Women." ScienceDaily. www.sciencedaily.com/releases/1999/04/990426062750.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins